<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pindolol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00960</strong>&#160; (APRD00678)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00960/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00960/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00960.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00960.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00960.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00960.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00960.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00960">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Betapindol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Blockin L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Blocklin L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Calvisken</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Decreten</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Durapindol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Glauco-Visken</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pectobloc</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pinbetol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prinodolol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pynastin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Visken</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Viskazide 10/25tab</td><td>Hydrochlorothiazide + Pindolol</td></tr><tr><td>Viskazide 10/50tab</td><td>Hydrochlorothiazide + Pindolol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>13523-86-9</td></tr><tr><th>Weight</th><td>Average: 248.3208<br>Monoisotopic: 248.152477894</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>JZQKKSLKJUAGIC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">[2-hydroxy-3-(1H-indol-4-yloxy)propyl](propan-2-yl)amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)NCC(O)COC1=CC=CC2=C1C=CN2</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00960.gif?1265922774">show</a>(8.77 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Indoles</td></tr><tr><th>Direct parent</th><td>Indoles</td></tr><tr><th>Alternative parents</th><td>Phenol Ethers; Alkyl Aryl Ethers; Pyrroles; Secondary Alcohols; 1,2-Aminoalcohols; Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>phenol ether; alkyl aryl ether; benzene; pyrrole; 1,2-aminoalcohol; secondary alcohol; ether; secondary amine; polyamine; secondary aliphatic amine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene  to form 2,3-benzopyrrole.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.</td></tr><tr><th>Pharmacodynamics</th><td>Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.</td></tr><tr><th>Mechanism of action</th><td>Pindolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.</td></tr><tr><th>Absorption</th><td>Rapidly and reproducibly absorbed (bioavailability greater than 95%).</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>2 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>40%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates.</p></td></tr><tr><th>Route of elimination</th><td>Pindolol undergoes extensive metabolism in animals and man. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. About 6% to 9% of an administered intravenous dose is excreted by the bile into the feces.</td></tr><tr><th>Half life</th><td>3 to 4 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>50-300 mL/min [cirrhotic patients]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Pindolol Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9951</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6929</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6667</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9272</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9423</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8179</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8315</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.708</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7809</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8331</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9218
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9367
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9843
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9438 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9404
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5774
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Genpharm pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Nostrum laboratories inc</li>
<li>Purepac pharmaceutical co</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.merckle.de">Merckle GmbH</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li>Novopharm Ltd.</li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00575">Clonidine</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Increased risk of bradycardia</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The beta-blocker, pindolol, may increase the toxicity of disopyramide.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Hypertension, then bradycardia</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00983">Formoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00047">Insulin Glargine</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>The beta-blocker increases the effect and toxicity of lidocaine</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00236">Pipobroman</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00938">Salmeterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01162">Terazosin</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Increased effect of both drugs</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Magnesium, potassium and zinc needs increased.</li>
<li>Take without regard to meals. Avoid alcohol.</li></ul></td></tr></tbody></table>